CRA provided expert testimony in litigation involving allegations that fraudulent reporting of list prices by pharmaceutical manufacturers affected reimbursement by insurers. CRA’s analyses addressed important features underlying pricing and reimbursement in the pharmaceutical industry, including the role of list prices and price reporting publications, the evolution of pricing mechanisms as a basis for reimbursement, and information held by various parties concerning pharmaceutical acquisition costs.
Paving the way for expanded GLP-1 coverage
GLP-1 agonists were originally approved to treat Type 2 Diabetes (T2D) – but their most recent incarnations, which consist of both next generation GLP-1s and...